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tion and may inform the future development of therapeutic
strategies for managing Acinetobacter infections.

The Acinetobacter baumannii-calcoaceticus complex is
comprised primarily of A. baumannii, Acinetobacter nosocomialis, Acinetobacter calcoaceticus, and Acinetobacter pittii,
nosocomial pathogens that are a frequent cause of serious multidrug-resistant infections associated with high mortality rates
(1) worldwide in immunocompromised individuals (2). Acinetobacter species possess several protein secretion systems,
including type I, type VI, and type II secretion systems (T2SS),4
which contributes to virulence (3–7). A zinc-dependent metalloendopeptidase CpaA is the most abundant T2SS substrate
(4) and CpaA expression and secretion is conserved across several medically-relevant Acinetobacter species (4, 8). Deletion of
CpaA results in attenuation of A. nosocomialis M2, establishing
the importance of this T2SS substrate in virulence (8). CpaA
had been previously shown to cleave factor V and deregulate
blood coagulation (9), and is required for virulence against Galleria mellonella larvae and is critical for dissemination of
A. nosocomialis to the spleen in a murine pulmonary model of
infection (8). The human coagulation factor XII (fXII) was
recently reported as a substrate of CpaA (10). It was shown that
CpaA cleaves factor XII at two sites Pro279–Thr280 and Pro308–
Thr309 located in the proline-rich domain of fXII between proline and O-linked glycosylated threonine. Deglycosylation of
fXII prevents cleavage by CpaA (10). However, why CpaA specifically targets glycosylated proteins is not understood.
Membrane-bound T2SS chaperone CpaB is required for the
stability and secretion of CpaA (4). This is reminiscent of the
Burkholderia glumae type II substrate, LipA, which requires a
membrane bound, lipase-specific foldase (Lif), to be folded into
its active form and secreted (11). Therefore, CpaB and Lif
belong to a unique class of T2SS, membrane-bound chaperones, which possess evident functional analogies. Their role in
T2SS is reminiscent of the type III secretion system (T3SS),
where the chaperones are soluble cytoplasmic proteins that aid
4

The abbreviations used are: T2SS, type II secretion system; Lif, lipase-specific
foldase; SAXS, small angle X-ray scattering; SAD, single-wavelength anomalous diffraction; ␤ME, ␤-mercaptoethanol; CD, catalytic domain; PD,
prodomain.
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Members of the Acinetobacter baumannii-calcoaceticus complex are nosocomial pathogens frequently causing multidrugresistant infections that are increasing at alarming rates. A. baumannii has become the Gram-negative bacterium with the
highest rate of multidrug resistance. As such, it is categorized by
the World Health Organization as a critical priority for the
research and development of new antimicrobial therapies. The
zinc-dependent metalloendopeptidase CpaA is a predominant
substrate of the type II secretion system (T2SS). CpaA is also a
virulence factor of medically relevant Acinetobacter strains that
specifically degrade the human glycoprotein coagulation factor
XII and not its deglycosylated form, but the mechanism for this
specificity is unknown. CpaB is a membrane-anchored T2SS
chaperone that interacts with CpaA and is required for its stability and secretion. Here, we report the crystal structure of the
CpaAB complex at 2.6-Å resolution, revealing four glycan-binding domains in CpaA that were not predicted from its primary
sequence and may explain CpaA’s glycoprotein-targeting activity. The structure of the complex identified a novel mode for
chaperone–protease interactions in which the protease surrounds the chaperone. The CpaAB organization was akin to
zymogen inactivation, with CpaB serving as a prodomain that
inhibits catalytically active CpaA. CpaB contains a C-terminal
tail that appears to block access to the CpaA catalytic site, and
functional experiments with truncated variants indicated that
this tail is dispensable for CpaA expression and secretion. Our
results provide new insight into the mechanism of CpaA secre-

The structure of CpaA complexed with its chaperone CpaB

Results
Overall structure of the CpaAB complex
We determined the crystal structure of metallopeptidase
CpaA in complex with the C-terminal periplasmic domain of its
chaperone CpaB by the single-wavelength anomalous diffraction (SAD) method using crystals of selenomethionine-incorporated protein to 2.6-Å resolution (Fig. 1, Fig. S1, and Table 1).
The protein constructs and residue numbering used in this
study compared with reference sequences of the proteins in
Acinetobacter are shown on Fig. S2. The electron density maps
are clearly interpretable for the majority of the complex and the
density explicitly defined the main and side chain atoms (Fig.
S3). There are six copies of the complex in the asymmetric unit.
Each copy is composed of one CpaA bound to one CpaB establishing the stoichiometry of the complex as 1:1. Due to specific
arrangement of chaperone-protease assembly where the protease surrounds the chaperone (Fig. 1), interactions between
CpaA and CpaB are prevalently intradimer contacts. This leads
to an average buried surface area of 2099.7 Å2 between CpaA
and CpaB. The next largest buried surface area is 560 Å2 that
occurs between two CpaA molecules. The large buried surface
area of ⬃2099.7 Å2 suggests the dimer of CpaA and CpaB
observed in the crystal structure is likely to occur in solution.
The structure reveals a modular architecture of CpaA that contains four very similar predominantly ␤-sheet repeats (domains

1 to 4), and a fifth domain with peptidase activity (catalytic
domain) (Fig. 1).
Small angle X-ray scattering (SAXS) of CpaAB demonstrates
the solution state is a 1:1 complex
To unambiguously establish the solution state and solution
structure of CpaAB we performed a SAXS analysis. SAXS profiles for CpaAB matched the crystal structure of the 1:1 complex very well with a 2 value of 1.02 (Fig. 2). The ab initio
envelope reconstruction from the SAXS profile resulted in an
envelope that closely resembles the 1:1 CpaAB crystal structure. These results demonstrate the crystal structure of the
CpaAB complex is representative of the solution state of
CpaAB, and that CpaA wraps around CpaB upon interaction in
solution.
Comparison of CpaAB to a known T2SS chaperone:substrate
complex
Each molecule of CpaB is embedded into the core of a CpaA
molecule through multiple interactions (Fig. 1). The only other
type II secretion chaperone:substrate complex studied of Lif/
LipA suggested a model in which the chaperone wraps around
the substrate and protects the cargo. In contrast, the CpaAB
complex reveals entirely different arrangement of chaperone–
protease interaction. Each CpaB chaperone is surrounded by
the CpaA protease (Fig. 3). This novel finding extends the
understanding of chaperone–substrate interplay.
CpaA contains a canonical zinc metalloprotease domain
The metalloprotease catalytic module immediately follows
repeat 4 and spans residues 372–574 (Figs. 1 and 4A, and Fig.
S2). This domain of CpaA resembles several features of the
canonical metzincin superfamily of metallopeptidases including a characteristic ␣⫹␤-fold, extended zinc-binding motif
HEXXHXXGXXH, and a conserved Met-turn (15) (Fig. 4B).
The three histidine residues (His498, His502, and His508) are
responsible for binding the catalytic zinc ion, the glutamate
residue (Glu499) is the general base/acid residue involved in
catalysis, whereas the Met-turn (Met527) assists in the folding
and provides stability to the catalytic domain (Fig. 4A and Fig.
S2) (17). To confirm these canonical metalloprotease features,
we generated a Glu499 to Ala point mutation and tested CpaA
activity in vitro. Mutation of CpaA Glu499 to Ala produced a
catalytically inactive protease incapable of degrading Factor V
(Fig. 5).
Another important structural feature observed is a stretch of
glycines (CpaA Gly466, Gly468, Gly469, and Gly471) (Fig. 4B). In
other metzincin superfamily members, this conserved glycine
stretch likely confers plasticity to the active site cleft and facilitates recognition of the O-glycan–induced conformation (16).
Finally, the peptidase domain also shows high structural similarity to adamalysins/ADAMs.
CpaA possesses four glycan-binding–like domains
The four tandem repeats of CpaA span residues 2–94 (repeat
1), 95–190 (repeat 2), 191–284 (repeat 3), and 285–371 (repeat
4). Pairwise superposition of repeats confirms they all share a
similar fold (Fig. 4C and Table S1). Structural similarity search
J. Biol. Chem. (2019) 294(36) 13344 –13354
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in folding, stabilization, and/or regulating secretion of T3SS
substrates (12, 13). However, CpaB and Lif chaperones do not
present any sequence similarity and are different in size and pI.
CpaB is the first reported membrane-bound, periplasmic chaperone required for secretion of a protease via a T2SS.
CpaA and CpaB interact strongly and the C-terminal
periplasmic domain of CpaB is sufficient for its chaperone function and interaction with CpaA, whereas the transmembrane
domain of CpaB keeps it tethered to the inner membrane preventing its secretion with CpaA (8). Although the necessity of
CpaB for secretion of CpaA has been established, whether its
role in secretion of CpaA goes beyond stabilizing CpaA has not
been determined. One possibility is that this interaction
inactivates CpaA preventing self-intoxication of the cell by
the proteolytic activity of CpaA. However, CpaB binding
appears not to block the proteolytic activity of CpaA against
human factor V (8).
The lack of structural information for the CpaAB complex, as
well as for each of the proteins alone, hinders the development
of strategies to treat antibiotic-resistant infections through the
inhibition of CpaA. The basis behind the specificity of CpaA for
glycosylated fXII is unknown (14). Here, we present the crystal
structure of the complex of CpaA from A. nosocomialis M2
with the entire periplasmic domain of its membrane-bound
chaperone CpaB at 2.6-Å resolution. These studies reveal novel
insight into chaperone–substrate interaction, proteolytic regulation, and substrate-specificity of an important T2SS substrate
and chaperone. The results of this study constitute a significant
advance in the development of novel antivirulence treatments
for Acinetobacter infections designed based on the structure of
CpaAB.

The structure of CpaA complexed with its chaperone CpaB
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Figure 1. Overall structure of the CpaAB complex. CpaA peptidase domain is colored in gray, four tandem repeats (1 to 4) are colored in shades of blue.
Chaperone CpaB is colored in orange. Contacting interfaces between CpaB and each subdomain of CpaA are shown as sticks in the color insets.

using the DALI server (17) revealed that these four repeats
resemble glycan-binding domains. Enterohemorrhagic Escherichia coli, zinc metalloprotease StcE (PDB ID 4DNY) (Fig. 4D)
specifically targets densely O-glycosylated substrates (16) and
shows structural similarity with all four repeats (Fig. 4, E–H):
Dali Z-score: 10.6, r.m.s. deviation 2.2 Å for repeat 1; Dali
Z-score: 8.4, r.m.s. deviation 2.7 Å for repeat 2; Dali Z-score:
10.4, r.m.s. deviation 1.9 Å for repeat 3; Dali Z-score: 8.3, r.m.s.
deviation 1.9 Å for repeat 4). The four repeats form a large
cavity with a buried surface area of 2,119 Å2 taken up by CpaB in
the complex. This large cavity may accommodate substrates
during proteolysis. Each CpaB molecule contacts all four

13346 J. Biol. Chem. (2019) 294(36) 13344 –13354

repeats potentially blocking access for binding of glycoprotein
substrates.
CpaA putative substrate-binding cleft
The structure showed a large cavity in the center of CpaA
formed by the contribution from all subdomains of CpaA
including the four tandem repeats and a peptidase domain. This
cavity comprises the active site located in the peptidase domain
and a large concave surface toward the catalytic site that may
serve for substrate recognition. However, the identity, recognition, and mode of interaction of CpaA proteolytic substrates
remain unknown.

The structure of CpaA complexed with its chaperone CpaB
Table 1
Data collection and refinement statistics
Data collection
Space group
Cell dimensions
a, b, c (Å)
␣, ␤, ␥ (°)
Resolution (Å)a
Rpim
I/I
CC(1/2)
Completeness, (%)
Redundancy
No. of reflections
Refinement
Rwork/Rfreeb (%)

a
b

110.747, 118.489, 129.583
108.94, 103.97, 100.10
50.0–2.60 (2.64–2.60)
4.0 (58.8)
16.7 (1.26)
0.99 (0.515)
96.8 (96.0)
3.5 (3.5)
173,168
22.55/23.99
31,899
116
293
0
1.62
98.38
0.002
0.465

Values in parentheses refer to the highest resolution shell.
Rfree ⫽ free R factor based on random 5% of all data.

Figure 2. SAXS analysis of CpaAB complex closely resembles the 1:1
CpaAB crystal structure. Plot of scattering intensity (I) against scattering
momentum (q) and statistical fit of theoretical scatter from the CpaAB crystal
structure (red line) with the experimental SAXS profile with a 2 value of 1.02.
Inset shows the ab initio envelope in white overlaid on the CpaAB structure
with CpaA in yellow and CpaB in orange.

Pairwise comparison of the six molecules of CpaA in the
asymmetric unit showed negligible r.m.s. deviations ranging
from 0.155 to 0.371 Å. A majority of the differences are in loops
of the protease domain, whereas the glycan-binding repeats
remain unchanged.
The structure and organization of CpaA provide insight
into potential substrate specificity. Structural superposition of
CpaA with metzincin superfamily members revealed several
unique structural elements that are typical for cleavage of
densely O-glycosylated substrates. StcE is a ⬃100 kDa metalloprotease that specifically interacts with O-glycosylated substrates (18, 19) and its INS domain has the highest DALI score
for all CpaA repeats.
The StcE INS glycan-binding domain contains a cluster of
conserved solvent-exposed residues, Trp189, Arg191, and Tyr214
(Fig. 4B), suitable for binding glycoproteins (16). Pairwise
superposition of the INS domain with each of the four CpaA
tandem repeats shows that all four repeats retain the solvent-

Figure 3. New complex organization in CpaAB. A, protease CpaA in complex with its type II secretion-chaperone CpaB. B, B. glumae lipase-specific
foldase in complex with its cognate lipase (PDB ID 2es4).

exposed loop containing a conserved tryptophan residue at the
same position, whereas the two other residues of the triad are
not conserved (Fig. 4, D–G). Curiously, only residue Lys34 of the
triad analogs in repeat 1 is involved in chaperone binding (Fig.
4D) and the corresponding loop is tilted toward the substratebinding cleft, whereas the analogous loops in all other repeats
are exposed to the solvent (Fig. 4A).
CpaB shares similarity to a protease prodomain
Metallopeptidase chaperone CpaB has no significant sequence similarity to any known protein. However, it shows high
structural similarity with the prodomain of Bacteroides fragilis
toxin (PDB ID 3p24, Dali score 5.8, r.m.s. deviation 2.8 Å), a
zinc-dependent metallopeptidase (20). CpaB consists of a large
twisted antiparallel ␤-sheet (strands ␤1 and ␤3–␤8), which vertically traverses the whole domain (Fig. 6A, Fig. S4). Strand ␤3 is
twisted and split between the vertical antiparallel ␤-sheet and a
small two-stranded antiparallel ␤-sheet (strands ␤2 and ␤3)
J. Biol. Chem. (2019) 294(36) 13344 –13354
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No. of atoms
Protein
Ligand/Ion
Water
Ramachandran (%)
Outliers
Allowed
Favored
R.m.s. deviations
Bond length Å)
Bond angles (°)

P1

The structure of CpaA complexed with its chaperone CpaB
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plus an adjacent antiparallel helix, ␣1. The helix is inserted
coplanar to the small sheet between strands ␤1 and ␤2. This
sheet is orthogonal to the large ␤-sheet and both give rise to a
␤-sandwich structure. The strands of the large ␤-sheet except
the ␤1 are linked by simple vertical connectivity from ␤3 to ␤8.
After strand ␤8, the polypeptide chain folds in short helix ␣2
and then adopts an extended coil conformation (chaperone
tail) that was found inserted in the CpaA active site and carries
an Asp residue that coordinates catalytic zinc together with the
His triad from CpaA (Figs. 1 and 6, B–D).
The CpaB tail blocks access to the CpaA catalytic site
In the CpaAB complex, the chaperone CpaB makes an
extended network of polar interactions with the protease
domain of CpaA (Table S2). The chaperone CpaB ␤-sheet
strands ␤4 –␤7 (residues Asp110, Arg113, Thr131, Asp136, Gln142,
Asp149, Gln153, and Lys155) interacts with CpaA helix 2 (residues Ser392, Leu393, Arg397, Glu400, and Asp531). In addition, the
CpaB tail embeds in the catalytic active site of CpaA creating
contacts between Gly167, Thr169, Asp170, and Glu172 of the
CpaB tail and Cys470, Ser492, and catalytic zinc coordination
partners His498, His502, and His508 of CpaA (Fig. 6B).

CpaB does not protect CpaA from self-proteolysis
Previously, we have observed that CpaA is unstable in the
absence of CpaB (8). To investigate whether CpaB prevents
the self-proteolysis of CpaA inside Acinetobacter cells, we
looked at protein levels of CpaAE499A (catalytically inactive
CpaA, Fig. 5) in the absence of CpaB by Western blot analy-

Figure 4. Tandem repeats (subdomains 1 to 4) of CpaA are structurally similar to glycoprotein-binding domains and its catalytic domain is similar to
metzincins. A, domain architecture of CpaA. Peptidase domain is colored gray, four successive repeats are colored as indicated on the figure. Solvent-exposed
putative glycan binding triads, containing conserved Trp, are shown as sticks. B, peptidase domain of CpaA possesses the standard elements of the substratebinding site of the canonical metzincin. Cyan, zinc coordinating residues. Green, conserved Met-turn. C, structural overlays of four repeats of CpaA are shown
in the color scheme as in A. Repeats pairwise overlays r.m.s. deviation are listed in Table S1. D, ribbon representation of the INS domain of glycoprotein
enterohemorrhagic E. coli StcE (PDB ID 4DNY) shown in cyan. Putative glycoprotein binding triad Trp189, Arg191, and Tyr214 of INS (16) is shown in sticks. E–H,
structural overlays of four repeats of CpaA with INS shown in cyan (Dali Z-score: 10.6, r.m.s. deviation 2.2 for repeat 1; Dali Z-score: 8.4, r.m.s. deviation 2.7 for
repeat 2; Dali Z-score: 10.4, r.m.s. deviation 1.9 for repeat 3; Dali Z-score: 8.3, r.m.s. deviation 1.9 for repeat 4). The color scheme for CpaA repeats is as in A.

J. Biol. Chem. (2019) 294(36) 13344 –13354
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Figure 5. CpaA Asp499 is required for activity. Human Factor V (FV) was
incubated with purified CpaA-His and CpaAE499A. Due to post-translational
modification heterogeneity, FV migrates in a SDS-PAGE gel as a smear (in
green). Full-length FV (high molecular weight smear) is detectable in the
buffer control and when incubated with CpaAE499A, indicating that
CpaAE499A is catalytically inactive.

The interaction between protease CpaA and chaperone
CpaB in CpaAB complex resembles interactions between the
catalytic domain (CD) and the prodomain (PD) of fragilysin-3
(PDB ID 3p24) (Fig. 6, D and E) (20). The catalytic fragilysin-3
moiety is unique within the metzincin metallopeptidases as it
shows high structural similarity despite negligible sequence
identity to adamalysins/ADAMs (20). The PD in fragilysin-3 is
thought to confer latency maintenance for the protein and
serves as a chaperone that assists in the folding and stabilization
of the fragilysin-3 catalytic domain. In the fragilysin-3 structure, the PD does not cap the CD but is attached to a lateral
surface (Fig. 6E). The PD prevents access to the active-site cleft
through the C-terminal segment, which runs in an extended
conformation across the entire CD active site in the opposite
orientation that substrates occupy. As in other prodomains, the
PD of fragilysin-3 prevents access of substrates to active-site
clefts of zymogens.
In addition to structural similarity between CpaB and the PD
of fragilysin-3, superposition of CpaA peptidase domain/CpaB
with fragilysin-3 reveals a similar organization of the domains
and functional elements (Fig. 6, D and E). The CD of fragilysin-3
like CpaA also contains an extended zinc-binding motif and a
conserved methionine within a tight 1,4-␤-turn, the Met-turn
(15, 21–25). The extended flexible fragment of the PD in fragilysin-3 traverses the catalytic domain of fragilysin similarly to
the tail of the chaperone CpaB in CpaAB complex and provides
the coordination partner for catalytic zinc (Fig. 6, D and E).
The fragilysin-3 PD plays a role in latency maintenance and
also functions as a chaperone that assists in the folding and
stabilization of the CD (20). The inhibitory mechanism follows
an “aspartate switch” that has been described for proastacin and
ADAMs/adamalysins (26). According to this mechanism, an
aspartate of the PD coordinates and inactivates the catalytic
zinc ion by replacing the solvent molecule usually found in
mature CDs primed for catalysis (27). The solvent is further
linked to a general base/acid, which is generally a glutamate. In
CpaA this general base/acid glutamate appears as Glu499. The
structural conservation suggests a similar mechanism of inhibition occurs for CpaA by CpaB.
The structure and organization of CpaA:CpaB complex provide insight into chaperone–substrate interaction and multiple
roles for this interaction can be proposed. Thus, in the following sections we attempted to evaluate some of them.

The structure of CpaA complexed with its chaperone CpaB
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sis. In a strain lacking CpaB, catalytically active CpaA is proteolytically cleaved into a 30-kDa fragment (Fig. S5). CpaA
also is cleaved into the 30-kDa fragment in the CpaAE499A
strain, indicating CpaA degradation is not due to autocatalytic cleavage but likely alternative host proteases cleaving
CpaA, maybe as a result of incorrect or aberrant folding due
to the absence of CpaB (Fig. S5).
The C-terminal tail of CpaB is dispensable for secretion of
CpaA

Discussion
The zinc-dependent metalloendopeptidase CpaA is secreted
by the T2SS and plays an important role in Acinetobacter virulence (4, 8, 14). It requires a chaperone CpaB for correct folding,
stability, and secretion (8). The protease and chaperone are
encoded adjacent to each other in the genome and interact
directly in the periplasm (8). However, the mechanism of the
interaction as well as a role of the chaperone is unclear. We
identified the molecular interactions involved in CpaA secretion through binding to its membrane-bound chaperone by
solving the crystal structure of the CpaA in the presence of the
C-terminal periplasmic domain of CpaB.
The structure showed that CpaA is reminiscent of metzincins (15) and possesses their superfamily features such as
characteristic ␣⫹␤-fold subdomains (1 to 4) with a glycan-

Figure 7. CpaB C-terminal tail is dispensable for secretion of CpaA. Whole
cells and supernatant preparations of A. nosocomialis ⌬cpaAB cells expressing CpaB WT and different CpaB mutant variants by Western blotting using
anti-CpaA and anti-His polyclonal antibody. A, all CpaB variants are expressed
in similar levels. B, CpaA degradation was not observed for any CpaB mutants
tested. C, CpaA is secreted at similar levels in all the strains. RNA polymerase
was used as a lysis control (anti-RNApol antibody).

binding domain–like fold, extended zinc-binding motif HEXXHXXGXXH, a conserved Met-turn and a glycine-rich stretch in
the catalytic domain. Mutagenesis of Glu499 to alanine abolishes CpaA-mediated cleavage of Factor V, confirming the
structurally predicted catalytic Glu499 is required for the proteolytic activity of CpaA. CpaA bears structural and functional
similarities to the E. coli–secreted glycoprotease StcE. However, both proteases share negligible sequence identity and
exhibit different domain organization (16). There is a large sub-

Figure 6. Structural similarity with fragilysin-3 suggests an inhibitory mechanism for CpaAB. A, structural overlay of CpaB with the prodomain (PD) of
fragilysin-3 (PDB ID 3p24, Dali Z-score: 5.8, r.m.s. deviation 2.8). Upper and lower panels are related by 90° rotation and shows CpaB in orange and PD in blue. B,
CpaA/CpaB interface. Interacting residues are shown as sticks, zinc as a red sphere, and CpaA and CpaB are colored gray and orange, respectively. C, an
electrostatic surface representation of CpaAB. Inset shows binding of the chaperone tail to a shallow solvent-exposed pocket in the catalytic domain of CpaA.
Residues making hydrogen bonds are shown as sticks and colored white or orange, respectively. Zinc ion is shown in magenta. Hydrogen bonds are presented
by dotted black lines. Zinc coordination environment is shown by a solid lines. D and E, structural similarity between CpaAB and fragilysin-3 suggests an
analogous inhibitory mechanism. Catalytic zinc coordination ligands and canonical Met in Met-turn are shown as sticks. CpaA and CpaB are colored gray and
orange, respectively (D). CD and PD of fragilysin-3 are shown in magenta and blue, respectively (E).
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13351

Downloaded from http://www.jbc.org/ at Washington University on December 2, 2019

CpaB is required for stability and secretion of CpaA (8). Furthermore, CpaB interacts with all four glycan-binding domains
of CpaA as well as the protease domain (Fig. 1). To investigate
what interactions are required for stability and secretion of
CpaA we generated CpaA glycan-binding domain deletions
and tested expression and secretion of CpaA (Fig. S6). Deletion
of one or more glycan-binding domains was sufficient to destabilize CpaA (Fig. S6). All glycan-binding domains of CpaA are
required for its stability. Additionally, CpaA and CpaB interact
through CpaB’s tail and the CpaA CD (Fig. 6B). The CpaB tail
embeds in the catalytic active site of CpaA creating contacts
between Gly167, Thr169, Asp170, and Glu172 of the CpaB tail and
Cys470, Ser492, and catalytic zinc coordination partners His498,
His502, and His508 of CpaA (Fig. 6B). To test the role of the CpaB
tail domain in stability and secretion of CpaA we created point
mutations of CpaB Asp170 and deleted the tail domain
(CpaB⌬167–178) (Fig. 7). The mutations were selected to interfere with the zinc coordination; either by changing the net
charge or the length of the interaction. All CpaB mutant variants were expressed and stable (Fig. 7A). We did not observe
any effect of CpaB tail on CpaA stability (Fig. 7B) and secretion
(Fig. 7C), not even when the entire C-tail was removed. Taken
together these results indicate that CpaB C-tail does not assist
on CpaA stability and secretion.
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and regulation providing a novel targeted strategy to the elimination of multidrug-resistant nosocomial infections.

Experimental procedures
Strains, plasmids, and growth conditions
Bacterial strains and plasmid used in this study can be located
in Table S3. E. coli Stellar and A. nosocomialis M2 cells were
grown in Lennox broth (LB) at 37 °C. pWH1266-based plasmids were selected with tetracycline (5 g/ml).
Protein expression, purification, and crystallization
Selenomethionine-substituted CpaAB (SeMet CpaAB) was
generated using the same expression construct (pETDUETCpaAHis-CpaB) and E. coli BL21 Rosetta 2 (Novagen) strain as
described (8). The constructs employed express the mature
form of CpaA and a soluble form of CpaB lacking its transmembrane domain. The constructs are represented in Fig. S2. Cells
were grown in SelenoMet Medium (M9 minimal media supplemented with glucose, vitamins, and amino acids, Molecular
Dimensions Ltd., MD12-501), ampicillin (100 mg/ml), and
chloramphenicol (12.5 mg/ml) at 37 °C until the A600 reached
⬃0.6. The following amino acids were added for 15 min before
isopropyl 1-thio-␤-D-galactopyranoside induction at 30 °C for
12 h: lysine, phenylalanine, and threonine (100 mg/liter each)
and isoleucine, leucine, valine, and DL-selenomethionine (50
mg/liter each). Purification was performed under the same conditions as described (8). Briefly, cells were pelleted at 8,000 ⫻ g
for 10 min, washed with 30 mM Tris, pH 8.0, and resuspended in
20 ml of 50 mM NaH2PO4, 300 mM NaCl, and 10 mM imidazole,
pH 8.0. Cells were lysed with two rounds of a cell disruptor
using 35 k.p.s.i. (Constant System ltd., Kennesaw, GA). Cell
lysates were clarified at 11,000 rpm for 30 min, 5 mM ␤-mercaptoethanol (␤ME) was added and the lysate was passed over a
nickel-nitrilotriacetic acid-agarose column (Gold Bio, St. Louis,
MO). After washing the column with 50 mM NaH2PO4, 5 mM
␤ME, 300 mM NaCl, and 25 mM imidazole, pH 8.0, and 50 mM
NaH2PO4, 300 mM NaCl, and 50 mM imidazole, pH 8.0, protein
was eluted with 50 mM NaH2PO4, 5 mM ␤ME, 300 mM NaCl,
and 250 mM imidazole, pH 8.0. Further purification was done
on a Superdex 200 gel filtration column in 100 mM NaCl, 10 mM
HEPES, pH 7.2. SeMet derivative crystals were obtained by sitting drop vapor diffusion at 18 °C by mixing 1.0 l of protein (15
mg/ml) and 1.0 l of seed stock. To prepare seed stock, the 1-l
drop containing the original clustered crystals (grown from 1.3
M magnesium sulfate, 0.1 M MES buffer, pH 6.5) was mixed with
9 l of well solution (1.28 M magnesium sulfate, 0.1 M MES
buffer, pH 6.5) and pipetted up and down. Crystals were cryoprotected by transfer to a well solution including 25% glycerol
for 30 s, plunged into liquid nitrogen, and kept at 100 K during
data collection.
Data collection and structure determination
Because both CpaA and CpaB have no sequence homologs
the structure of the complex was determined by selenium SAD.
The data collection was performed at the selenium peak wavelength to 2.6-Å resolution at the Advanced Photon Source
23-IDD beamline. Data were processed with HKL-3000 (28).
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strate-binding cleft in the center of CpaA formed by the residues from four structurally similar tandem repeats and the peptidase domain. A glycine-rich stretch on the peptidase domain
region, contributing to the cleft, confers high conformational
freedom to the polyglycine backbone and facilitates recognition
of the O-glycan induced conformation. The presence of glycanlike binding domains explains why glycosylation of proteins is
required for CpaA activity (14). Our data suggests a potential
mechanism by which CpaA specifically targets its substrates
through the interactions of its glycan-binding domains with the
glycan epitopes on target proteins (10).
CpaB and Lif belong to a novel class of T2SS chaperones,
which possess evident functional analogies. In contrast to the
functionally related Lif chaperone required for folding and
secretion of LipA (11), chaperone CpaB does not engulf the
cognate effector protein but instead is surrounded by the protease. This is an unusual arrangement and provides new understanding of chaperone binding and possible function. The
results presented here suggest a putative regulatory mechanism
more akin to zymogen regulation. The CpaAB complex is stabilized by an extended network of hydrogen bonds and salt
bridges between CpaA and CpaB (Table S2). These interactions
ensure a strong interaction between the two proteins. CpaB tail
residues Gly167–His175 form several interactions with CpaA.
Despite the requirement of CpaB for secretion and stability of
CpaA, the tail region of CpaB is not responsible for those
functions.
In the absence of CpaB, CpaA is cleaved into a 30-kDa fragment. We determined that this fragment is not generated by an
autocatalytic cleavage event in the absence of CpaB. In addition
to the stabilizing protein–protein interactions, the CpaB tail
(residues Gly167–His175) forms hydrogen bonds with the amino
backbone groups of Cys470, Ser492, and His508, and the imidazole nitrogen atoms of His498 and His508 in the CpaA catalytic
domain (Fig. 6, B and C). A zinc ion required for CpaA peptidase activity is found at the catalytic site, also located at the
interface between CpaA and CpaB. The catalytic triad of His498,
His502, and His508 of CpaA make a zinc-coordination sphere
that adopts tetrahedral coordination geometry (Fig. 6C). In
addition, Asp170 of the CpaB tail is the fourth coordination
ligand for the zinc ion. One possibility is that CpaB limits accessibility to the catalytic triad of CpaA and is a possible mechanism of inactivation of the CpaA to prevent self-intoxication of
the cell prior to secretion. Therefore, the CpaB chaperone may
serve as an immunity protein that shields Acinetobacter from
CpaA peptidase activity.
We have previously shown that CpaB lacking its membrane
domain is secreted along with CpaB (8). Displacement of CpaB
through a putative interaction with the T2SS machinery would
be required to dissociate the chaperone from the protease. It is
tempting to speculate that CpaB can additionally contribute to
target CpaA to the secretion machinery.
The elucidation of the structure of CpaAB is one important
step toward the design of novel antivirulence treatments for
Acinetobacter infections through the structure-based development of CpaA-specific inhibitors. This study opens a new page
in the understanding of chaperone–secreted protein interactions and extends our knowledge of type II substrate secretion

The structure of CpaA complexed with its chaperone CpaB

Small angle X-ray scattering
Data for the CpaAB complex were collected at the SIBYLS
beamline 12.3.1 at ALS using standard procedures (34), and
analyzed using the ATSAS package, version 2.8.3 (35). A series
of 0.3-s exposures were collected at 0.5, 1, and 2 mg/ml of
CpaAB in 10 mM HEPES, pH 7.4, 150 mM NaCl in triplicate. The
first 12 exposures of each collection were analyzed and merged
using SAXS FrameSlice (sibyls.als.lbl.gov/ran).5 The triplicate
concentration runs were assessed and merged using PRIMUS.
Experimental profiles were compared with the structure using
CRYSOL. Ab initio model generation was performed in DAMMIF, and the filtered average envelope of 10 models was
obtained by DAMAVER. SUPCOMB was used to align structures and SAXS reconstructions.
Generation of CpaA and CpaB point mutations and deletions
The polymerase chain reaction (PCR) primers used for sitedirected mutagenesis are listed in Table S4. To generate a catalytically inactive, and the truncated variants of CpaA, pWHcpaA-his-cpaB (4) was used as the template. To generate single
and double amino acid substitutions, and the truncations in
CpaB, pWH-cpaA-cpaB-his (8) was used as template. PCR was
carried out using Phusion DNA Polymerase (Thermo Scientific). Site-directed mutagenesis was performed according to
the method described by Fisher and Pei (36). Truncation variants were generated using the In-fusion HD EcoDry cloning kit.
The ligation products were transformed into E. coli Stellar cells
and transformants were selected in LB-agar supplement with
tetracycline. Transformants were subcultured and the plasmids
5
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were purified and verified by sequencing. The pWH-based
constructs were then electroporated into electrocompetent
A. nosocomialis M2 ⌬cpaAB::frt strains.
Immunoblotting
Bacterial secretion whole-cell and supernatant samples were
prepared as published previously (4, 8). Briefly, cultures were
grown to 0.5 AU/ml, and 0.5 AU was pelleted by centrifugation
and resuspended in 50 l of 1⫻ Laemmli buffer for the wholecell samples. Supernatant samples were obtained by TCA-precipitating cell-free supernatants as published previously (7).
Proteins were resolved by SDS-PAGE analysis and transferred
to a nitrocellulose membrane by semidry transfer and probed
with either polyclonal anti-histidine (1:2000, Pierce), polyclonal
anti-CpaA (1:1000 (8)), and/or monoclonal anti-RNA polymerase (1:2000, Biolegend). Western blots were probed with
IRDye-conjugated secondary antibodies and visualized with an
Odyssey CLx imaging system (LI-COR Biosciences, Lincoln,
NE).
Factor V cleavage assay
CpaA-His or CpaAE499A-His were purified out of the
supernatant of A. nosocomialis M2. Briefly, A. nosocomialis
⌬cpaAB::frt carrying pWH-cpaA-his-cpaB or pMFH32 was
grown in LB supplemented with tetracycline to mid-log phase.
His-tagged proteins were purified from cell-free supernatants
through nickel affinity chromatography as above. The purified
proteins were concentrated, and the buffer was changed to 20
mM HEPES, 150 mM NaCl, and 50% glycerol, pH 7.4, using
Amicon Ultra centrifugal filter units.
The Factor V cleavage assay was carried out according to
Kinsella et al. (8). Briefly, 1.6 g of purified CpaA or
CpaAE499A (in 20 mM HEPES, 150 mM NaCl, and 50% glycerol,
pH 7.4) was mixed with 11 ng of human Factor V (Abcam,
Cambridge, MA) in a total volume of 20 l (20 mM HEPES and
150 mM NaCl, pH 7.4). All samples were incubated at 37 °C for
30 min. Factor V cleavage was monitored by Western blotting
by resolving 8.2 ng of Factor V per lane on an 8% polyacrylamide
gel. Factor V was detected using polyclonal sheep anti-human
Factor V (Thermo Fisher, 1:1,000), polyclonal rabbit anti-sheep
Ig (Fc-specific, Sigma, 1:12,000), and IRDYE威 800CW goat
anti-rabbit IgG (LI-COR, 1:15,000). CpaA-His was detected
with monoclonal mouse anti-His6 (Thermo Fisher, 1:1000) and
IRDYE威 680RD goat anti-mouse IgG (LI-COR, 1:15,000).
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The anomalous completeness of the data were 98.3% (87.2% in
outer shell), with an anomalous multiplicity of 12.0 overall (7.0
in outer shell). Anomalous correlation between half-sets was
0.760 in the inner shell and 0.280 overall. SHELXC, SHELXD,
and SHELXE (29) were used in pipeline for substructure determination and phase approximation. SHELXC found 72 selenium atoms of 72 possible selenium sites. Phasing was done
with MLPHARE (30) followed by density modification carried
out by DM (30). The initial model was built by Buccaneer (30)
and refined in Refmac5 (31) coupled with Parrot (30) for further
density modification and manual model correction in COOT
(32). The structure model was refined with Refmac5 to Rwork/
Rfree factors as 23.6/28.5%. Then the refinement was carried on
with Phenix (33) to the final Rwork/Rfree factors as 21.5/23.3%.
The Ramachandran plot showed that 100% of residues were
allowed with 96.84% in the preferred region. The electron density maps are clearly interpretable for the majority of the complex with a few exceptions for the N terminus of CpaA chains C
(residue range 2–35, 40 – 48, 53–58, and 84 –90) and F (residues
2–5, 29 –32, and 53–56) and for the N-terminal residues of
CpaB chain G (residues 1–31, 50 – 65), chain H (residues 1– 41,
50 – 65), chain K (residues 1–39, 49 – 66), chain L (residues
1–28, 50 – 65), chain M (residues 1–31, 50 – 65), and chain N
(residues 1–36, 50 – 64), which are disordered. X-ray data and
refinement statistics are shown in Table 1.
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